Zeto Partners with Firefly Neuroscience to Enhance EEG Technology with AI Integration

Zeto, a leading AI company, has partnered with Firefly Neuroscience to distribute its FDA-cleared EEG headsets, Zeto ONE and WR19. As part of the agreement, Firefly will act as a non-exclusive distributor and integrate its Brain Network Analytics (BNA) technology into Zeto’s EEG platforms. These headsets, already in use at over 200 hospitals and neurology offices across the US, promise to offer deeper insights into neurological health.

Zeto ONE features 21 soft-tip electrodes using the internationally recognized 10-20 EEG system for standardized placement. It requires minimal training and provides real-time video, audio, and AI-enabled seizure notifications, all streamed to the Zeto Cloud for live remote analysis by neurologists. WR19, approved by the FDA in 2020, is a wireless dry-electrode EEG headset that offers gel-tip electrodes without requiring skin preparation or leaving residue. Clinical studies showed its performance matches traditional EEG systems.

EEG tests monitor brain electrical activity and aid in diagnosing conditions like epilepsy, sleep disorders, and brain tumors. The partnership aims to combine Zeto’s cutting-edge EEG hardware with Firefly's AI-powered BNA platform, enhancing diagnostic capabilities and improving patient outcomes.

AI-driven EEG solutions are gaining traction. Similar advancements by Ceribell in 2024 demonstrated a reduction in ICU stays and patient disabilities. The medical AI market is poised for significant growth, projected to reach $1.2 billion by 2027.

Jon Olsen, Firefly’s CEO, remarked that this partnership marks a significant step forward in advancing brain health diagnostics through AI innovation.